Share on

Global Dry Eye Syndrome Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Type, Product, Distribution Channel & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Industry Forecast (2022 to 2027)

Published: March, 2022
ID: 12886
Pages: 190
Formats: report pdf report excel report power bi report ppt

Global Dry Eye Syndrome Market Size (2022 to 2027)

The global market size for dry eye syndrome is projected to be growing at a CAGR of 5.22% from 2022 to 2027 and worth USD 8.29 billion by 2027 from USD 6.43 billion in 2022.

Dry eye syndrome, medically known as keratoconjunctivitis sicca, is a term that defines the lack of lubrication or moisture on the surface of the infected person's eyes. Dry eye is an ocular surface condition that causes the eye to produce insufficient tears and is associated with symptoms of ocular discomfort. Keratitis sicca, keratoconjunctivitis sicca (KCS), xerophthalmia, dry eye syndrome (DES), and dysfunctional tear syndrome are all terms for dry eye illness (DTS).

Dry syndrome is a prevalent condition that can affect almost everyone. Dry eyes can cause aching and burning feelings, weary eyes, red eyes, itchy eyes, irritated eyes, photophobia, and other symptoms. Aside from that, watery eyes may be a symptom because the dry surface of the eyes overstimulates the watery component of tears to relieve dryness.

Impact of COVID-19 on the global dry eye syndrome market:

Due to the nationwide lockdown and temporary suspension of economies and industries, the global pandemic had a moderately unfavorable influence on the dry eye syndrome therapy market. The Disease transmission rate was significant, hampered the concerning operations, and resulted in a transportation prohibition. Furthermore, the government's principal aim was to combat COVID-19. To meet the needs of a pandemic, healthcare professionals were swiftly altering their practice and purchasing priorities. As a result, the DED therapy was prioritized, resulting in the cancellation of the eye-check-up.

Most countries, however, permitted urgent and necessary treatments. Furthermore, the American Society of Retina Specialists issued guidelines to assist retina practices and medical workers in lowering the risk and ensuring the patients' health and safety during the COVID-19 pandemic. 


Y-O-Y rise in the prevalence of diabetes, rheumatoid arthritis, and thyroid diseases contributes to the prevalence of dry eyes, which is estimated to fuel the global dry eye syndrome market.

The growing geriatric population significantly contributes to the global dry eye syndrome market. The most common dry eye is associated with chronic ophthalmic disorders, which are usually witnessed in older people compared to adults. According to the WHO reports, around 9% of the global population is above 65 years of age, which is estimated that by 2050, it will witness 17% of the worldwide population.  There has been a considerable rise in eye care centers since primary eye care is now in the optical shop itself. Moreover, the new optical shops unveiled have the latest technological devices, which improve user-friendliness. Therefore, the technological advancements and the growing adoption of innovative products boost the market growth. 

The most common eye disease is associated with chronic ophthalmic disorders; the growing awareness about the availability of advanced dry eye treatment encourages the development. Increasing healthcare expenditure by the government and non-government organizations and understanding among the people promote the growth of the global dry eye syndrome market. The pharmaceutical companies' research and development activities are expected to provide lucrative growth opportunities.  Further, the leading manufacturers in the market are focussing on developing advanced products, OTC ointments, and eye drops which is accelerating the market growth. 


However, the high cost of specialty dry eye products and the unfavorable reimbursement policies are expected to restrain the market growth. Also, the availability of alternative therapies is further predicted to limit the development of the global dry eye syndrome market. 




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Drug Type, Product, Distribution Channel & Region


Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global dry eye syndrome market has been segmented and sub-segmented based on the drug type, product, distribution channel, and region.

Global Dry Eye Syndrome Market - By Drug Type:

  • Anti-inflammatory Drugs
  • Lubricant Eye Drops
  • Autologous Serum Eye Drops
  • Anti-Allergic
  • Anti-Infectives
  • Other 

Based on the drug type, the anti-inflammatory drugs segment accounted for the largest share of the market, and it is projected to grow at a significant pace during the forecast period. The increasing prevalence of eye syndrome cases and technological advancements in the treatment procedures such as artificial tears and lubricant eye drops are boosting the market growth. 

Global Dry Eye Syndrome Market - By Product:

  • Liquid Drops
  • Gel
  • Liquid Wipes
  • Eye Ointment
  • Others

The liquid drops segment held a significant share of the market during the forecast period. 

Global Dry Eye Syndrome Market - By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Specialty clinics
  • e-commerce
  • Others

Based on the distribution, the hospital pharmacies segment recorded the largest share of the market, and it is anticipated to witness a significant share during the forecast period. The increasing patient population is boosting the market growth because of the high preference given to hospitals. The majority of the medicines can only be prescribed after thorough examinations by the doctors.

Global Dry Eye Syndrome Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

North America is estimated to dominate the dry eye syndrome market during the forecast period. The regional market growth is attributed to the presence of significant market players, well-established healthcare infrastructure, and favorable reimbursement policies. The global level emerging countries such as the United States and Canada majorly contribute to North American regional market growth. The United States accounted for the largest share of the market, and it is likely to continue its growth in the coming period. The increasing prevalence of dry eye syndrome cases, growing awareness, technological advancements, and high healthcare spending are propelling the market growth. Based on the National Health and Wellness Survey data, 6.8 percent of the United States adult population (approximately 16.4 million people) are diagnosed with DED.

Europe is estimated to be the second-largest market for the dry eye syndrome market. Evolving healthcare sector, increasing prevalence of various diseases, growing geriatric population, and technological advancements in the healthcare sector are boosting the market growth. Also, significant pharmaceutical companies in new therapeutics and emerging markets such as Germany, the UK, France, Spain, and Italy are significantly contributing to the regional market growth. Germany is the primary growth contributor in Europe. It is the most capable market for properly developing and accepting novel drugs to diagnose dry eye syndrome. Also, the presence of qualified healthcare professionals, advanced companies, and technologically advanced technology are uplifting the market growth.  

The Asia Pacific is projected to grow significantly with a substantial CAGR during the forecast period. The factors such as environmental pollution levels in the region, growing population, favorable reimbursement policies, and improving the healthcare sector are fuelling the market growth. In the Asia Pacific, the Chinese market is the major contributor to market growth. Geriatric population growth, technological breakthroughs, and more research and development. According to a questionnaire, dry eye symptoms were reported by roughly 21% of the adult population in China, with links to age, female gender, metropolitan location, and refractive error under-correction. On the other hand, the Indian market is projected to witness a promising share due to the growing population, modern lifestyles, improving healthcare sectors, and supportive government policies. According to the healthcare statistics, the DED prevalence in India is higher than the global prevalence and ranges from 18.4% to 54.3%.


Alimera Science, Alcon Inc., Santen Pharmaceutical Co. Ltd., Allergan plc., Auven Therapeutics, Bausch + Lomb, GlaxoSmithKline plc, Bausch Health Companies Inc., Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., AbbVie Inc. (Allergan PLC) and OASIS Medical are a few of the prominent companies operating in the global dry eye syndrome market profiled in this report.


  • In May 2019, Novartis agreed to buy 5% of the assets related to Xiidra (lifitegrast ophthalmic solution) from Takeda Pharmaceutical Company Limited (Takeda). This is the first and only prescription medication licensed to treat dry eye signs and symptoms by inhibiting the disease's inflammation.
  • ReGenTree launched the Phase – III clinical trial (ARISE-3 Study) of the novel pipeline drug candidate RGN-259 as a dry eye treatment for dry eye syndrome in February 2019.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample